New Drugs: The Haystack Gets Smaller
Recombinant insulin, EPO, TPA. Together, these big-sellers and a half dozen other biotech drugs accounted for $5 billion in revenues last year. They also share a common biological trait: They are all genetically engineered versions of proteins naturally secreted into the body by human cells. Secreted proteins are the workhorses of the body, conveying messages from one cell to another and playing key roles in countless bodily functions. They are also among the most highly sought-after candidates for new drugs.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- U.S. Senate Adopts Budget, Giving Momentum to Trump's Tax-Cut Plans